NCT06663111 Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
| NCT ID | NCT06663111 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Haukeland University Hospital |
| Condition | Relapsing Remitting Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2021-03-15 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2021-03-15 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Eligibility Criteria
Inclusion Criteria: * Included in OVERLORD-MS (NCT04578639) * Willing to attend laboratory for blood sample collection at scheduled time points Exclusion criteria: \* Not willing to attend laboratory for blood sample collection at scheduled time points
Contact & Investigator
Trond T. Serkland, M.D.
PRINCIPAL INVESTIGATOR
Haukeland University Hospital
Frequently Asked Questions
Who can join the NCT06663111 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Relapsing Remitting Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06663111 currently recruiting?
Yes, NCT06663111 is actively recruiting participants. Contact the research team at trond.tretteberg.serkland@helse-bergen.no for enrollment information.
Where is the NCT06663111 trial being conducted?
This trial is being conducted at Bergen, Norway.
Who is sponsoring the NCT06663111 clinical trial?
NCT06663111 is sponsored by Haukeland University Hospital. The principal investigator is Trond T. Serkland, M.D. at Haukeland University Hospital. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.